ESTA vs. AVNS, ENOV, IRWD, VRNA, RCKT, FGEN, XNCR, SLRN, RDNT, and KDNY
Should you be buying Establishment Labs stock or one of its competitors? The main competitors of Establishment Labs include Avanos Medical (AVNS), Enovis (ENOV), Ironwood Pharmaceuticals (IRWD), Verona Pharma (VRNA), Rocket Pharmaceuticals (RCKT), FibroGen (FGEN), Xencor (XNCR), Acelyrin (SLRN), RadNet (RDNT), and Chinook Therapeutics (KDNY). These companies are all part of the "medical" sector.
Establishment Labs vs.
Establishment Labs (NASDAQ:ESTA) and Avanos Medical (NYSE:AVNS) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, media sentiment, analyst recommendations, community ranking, dividends, earnings, institutional ownership and profitability.
In the previous week, Avanos Medical had 2 more articles in the media than Establishment Labs. MarketBeat recorded 3 mentions for Avanos Medical and 1 mentions for Establishment Labs. Avanos Medical's average media sentiment score of 1.59 beat Establishment Labs' score of 0.78 indicating that Avanos Medical is being referred to more favorably in the news media.
Establishment Labs currently has a consensus price target of $95.20, suggesting a potential upside of 43.40%. Avanos Medical has a consensus price target of $30.25, suggesting a potential upside of 18.26%. Given Establishment Labs' stronger consensus rating and higher possible upside, analysts plainly believe Establishment Labs is more favorable than Avanos Medical.
Avanos Medical has a net margin of 5.34% compared to Establishment Labs' net margin of -47.84%. Avanos Medical's return on equity of 6.11% beat Establishment Labs' return on equity.
Establishment Labs has a beta of 1.01, meaning that its share price is 1% more volatile than the S&P 500. Comparatively, Avanos Medical has a beta of 0.92, meaning that its share price is 8% less volatile than the S&P 500.
Avanos Medical has higher revenue and earnings than Establishment Labs. Establishment Labs is trading at a lower price-to-earnings ratio than Avanos Medical, indicating that it is currently the more affordable of the two stocks.
Establishment Labs received 22 more outperform votes than Avanos Medical when rated by MarketBeat users. Likewise, 60.23% of users gave Establishment Labs an outperform vote while only 56.64% of users gave Avanos Medical an outperform vote.
75.3% of Establishment Labs shares are owned by institutional investors. Comparatively, 92.1% of Avanos Medical shares are owned by institutional investors. 12.6% of Establishment Labs shares are owned by insiders. Comparatively, 2.9% of Avanos Medical shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
Avanos Medical beats Establishment Labs on 10 of the 18 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ESTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Establishment Labs Competitors List
Related Companies and Tools